On Friday, Shares of Mattel, Inc. (NASDAQ:MAT), gained 6.04% to $23.89. The stock attained the volume of 15.62 million shares.
For the third quarter of 2015, Mattel, Inc. (MAT) stated worldwide net sales down 4% in constant currency, adjusted operating income of $321.6 million and adjusted earnings per share of $0.71.
Financial Overview
For the quarter, worldwide net sales were down 4% in constant currency contrast to last year. In the North American Region, which comprises of the United States, Canada and American Girl, third quarter gross sales reduced by 4% in constant currency, and 5% as stated. In the International Region, gross sales reduced by 2% in constant currency, and reduced 19% as stated. Adjusted gross margin reduced 170 basis points and 140 basis points as stated, primarily from the negative impact from changes in currency exchange rates. Adjusted other selling and administrative expenses reduced $30 million, reflecting continued cost improvement initiatives. Adjusted operating income for the quarter was $321.6 million, contrast to preceding year’s adjusted operating income of $434.5 million, reflecting the negative impact from changes in currency exchange rates and lower sales, partially offset by lower other selling and administrative expenses.
Capital Deployment
The Board of Directors declared a fourth quarter cash dividend of $0.38 per share, which is flat contrast to the fourth quarter of 2014. The dividend will be payable on December 11, 2015 to stockholders of record on November 25, 2015.
Mattel, Inc. designs, manufactures, and markets a range of toy products worldwide. The company operates in three segments: North America, International, and American Girl. It offers dolls and accessories, vehicles and play sets, and games and puzzles under the Mattel Girls & Boys brands, counting Barbie, Monster High, Disney Classics, Ever After High, Little Mommy, Polly Pocket, Hot Wheels, Matchbox, CARS, Disney Planes, BOOMco, Radica, Toy Story, Max Steel, WWE Wrestling, and Batman.
Shares of Wynn Resorts, Limited (NASDAQ:WYNN), dropped -1.17% to $72.90, during its last trading session.
Wynn Resorts, Limited (WYNN) declared the appointment of Clark T. “Sandy” Randt, Jr. and Patricia Mulroy to its Board of Directors, effective October 15, 2015. Ambassador Randt and Ms. Mulroy have been designated as Class III (with a term expiring at the 2017 Annual Meeting) and Class I (with a term expiring at the 2018 Annual Meeting) Directors, respectively. Ms. Mulroy will also serve on the Board’s Compensation and Nominating and Corporate Governance Committees. With the appointment of Ambassador Randt and Ms. Mulroy, the Wynn Board of Directors now comprises of nine Directors, seven of whom are independent.
Patricia Mulroy brings more than 30 years of regional government experience to the Board, performing in numerous leadership roles focusing on Nevada’s public infrastructure. Most recently, she served as a Commissioner of the Nevada Gaming Commission and a member of the Global Agenda Council on Water of the World Economic Forum. Proceeding to that, she served as General Manager of the Southern Nevada Water Authority from 1993 to 2014 and was the General Manager of the Las Vegas Valley Water District from 1989 to 2014.
Your ads will be inserted here by
Easy Plugin for AdSense.
Please go to the plugin admin page to
Paste your ad code OR
Suppress this ad slot.
Wynn Resorts, Limited, together with its auxiliaries, develops, owns, and operates destination casino resorts. It operates in two segments, Macau Operations and Las Vegas Operations.
Finally, Pfizer Inc. (NYSE:PFE), ended its last trade with 0.97% gain, and closed at $34.41.
Pfizer Inc. (PFE) declared it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib citrate) for the treatment of adult patients with moderate to severe chronic plaque psoriasis. The Agency offered recommendations specific to the moderate to severe chronic plaque psoriasis sNDA. Pfizer will work with the Agency to determine an appropriate path forward to address their comments, counting providing additional safety analyses of XELJANZ for the projected indication.
Psoriasis affects 7.4 million people in the United States.1 The most common form is plaque psoriasis, which affects about 80 percent of people who have the condition.2a Of those, as many as 20 percent have moderate to severe chronic plaque psoriasis.2b
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
